Medication Development for Treatment of Alcoholism

治疗酒精中毒的药物开发

• 批准号: 7944098
• 负责人: Robert A Harris
• 金额: $ 84.94万
• 依托单位: UNIVERSITY OF TEXAS AT AUSTIN
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-30 至 2012-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7944098
• 关键词: Medication; Development; Treatment; Alcoholism

DESCRIPTION (provided by applicant): This three-year funding proposal for a P20 Center provides a new paradigm for medication development for the treatment of alcoholism by bringing experienced alcohol researchers together with experts in chemistry, proteomics, gene delivery and Drosophila genetics who are new to the alcohol field. The goal is to develop the technologies and collaborations necessary to define new targets for medication development and translate our knowledge of alcohol targets into selective ligands. The Center consists of an Administrative Core (Adron Harris, PI and Center Director), target identification by neuron-specific transcriptomics (Igor Ponomarev, PI), target identification by proteomics (Dayne Mayfield, PI), ligand selection by high throughput screening (John Mihic, PI), and an Animal Core (Yuri Blednov, PI) to provide mice and behavioral testing to the projects. In addition, we propose two Pilot Projects (two years in duration) to develop technology to test the biological importance of new targets. One will provide tools to deliver inhibitory RNAs (RNAi) to the brain (Maria Croyle, PI) and another will develop knock-in Drosophila carrying mutations in target genes (Nigel Atkinson, PI). The Center has both internal and external advisory boards, providing expert guidance from scientists with a wide range of expertise. A key aim is to provide the collaborations and infrastructure necessary for a future P50 application which will focus new researchers and new technologies on medication development for alcohol dependence.

描述（由申请人提供）：这项针对 P20 中心的为期三年的资助提案，通过将经验丰富的酒精研究人员与化学、蛋白质组学、基因传递和果蝇遗传学方面刚接触酒精领域的专家聚集在一起，为治疗酒精中毒的药物开发提供了新的范式。目标是开发必要的技术和合作来定义药物开发的新靶点，并将我们对酒精靶点的知识转化为选择性配体。该中心由行政核心（Adron Harris，PI 和中心主任）、神经元特异性转录组学靶点识别（Igor Ponomarev，PI）、蛋白质组学靶点识别（Dayne Mayfield，PI）、高通量筛选配体选择（John Mihic，PI）和动物核心（Yuri Blednov，PI）组成，为项目提供小鼠和行为测试。此外，我们提出了两个试点项目（持续两年）来开发技术来测试新靶标的生物学重要性。其中一项将提供向大脑传递抑制性 RNA (RNAi) 的工具（Maria Croyle，PI），另一项将开发携带目标基因突变的果蝇（Nigel Atkinson，PI）。该中心设有内部和外部顾问委员会，由具有广泛专业知识的科学家提供专家指导。一个关键目标是为未来 P50 应用提供必要的合作和基础设施，该应用将集中新研究人员和新技术来开发酒精依赖药物。